H.I.G. Capital News
CardioFocus® Announces Full Commercial Launch of HeartLight® System in Japan
MARLBOROUGH, MA – July 11, 2018 - CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for atrial fibrillation (AF), today announced the commercial launch of its HeartLight Endoscopic Ablation System in Japan. The commercial launch will be managed in conjunction with its distribution partner JapanLifeline Co., Ltd. (JLL).
The commercial launch follows the country-wide reimbursement approval under Japan's National Health Insurance granted this month and the Japanese Ministry of Health, Labour and Welfare regulatory approval received in July 2017.
As a CardioFocus distribution partner, JLL will sell the HeartLight System to hospitals in Japan through its electrophysiology division, which includes more than 250 field personnel across 47 offices.
The HeartLight System is a visually-guided laser balloon technology for controlled and consistent pulmonary vein isolation (PVI) treatment of AF. Its direct visualization, titratable laser energy, and universal balloon design make it a new standard for PVI procedures. It provides an effective and safe treatment option for patients whose heart arrhythmias are insufficiently controlled with medication.
"We established our partnership with JLL in 2014 and have been systematically planning for this commercial rollout ever since," said Paul A. LaViolette, executive chairman of CardioFocus. "We are pleased to now offer our innovative technology to the Japanese market and look forward to achieving substantial growth over the coming years."
About CardioFocus, Inc.
CardioFocus is a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). The company's HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout the U.S., Europe and Japan. The HeartLight System is a revolutionary catheter ablation technology designed for the treatment of atrial fibrillation (AF), the most common heart arrhythmia. More than 5,000 patients with AF have been successfully treated with the system. CardioFocus is headquartered in Marlborough, Mass. www.cardiofocus.com.
About Japan Lifeline Co., Ltd.
Japan Lifeline (JLL) has a 36-year history as a manufacturer, importer and distributor of quality medical products. JLL has a strong track record of success in building and expanding markets with unique products from some of the world's leading medical technology companies. Japan Lifeline is a publicly traded company, ticker symbol 7575 (TSE 1st Section). Visit the JLL website at http://www.japanlifeline.com.
SOURCE CardioFocus, Inc.